Abstract:Objective:To investigate the protein expression of osteosarcoma stem cell surface biomarkers, CD117 and Stro-1, and their relationship with the clinicopathologic characteristics as well as disease-free survival (DFS).Methods:A retrospective study was adopted. Fifty-eight patients with osteosarcoma who were surgically removed and confirmed by pathological examination in Shanghai Jiao Tong University Affiliated Sixth People's Hospital from August 2014 to November 2017 were selected as the observation group, and 13 cases of adjacent bone tissue were used as the control group. Among them, 36 were male and 22 were female. Age 10-67 (23.16 ± 13.47) years. All tissue were collected to construct tissue microarrays. Immunohistochemistry was used to detect the expression of osteosarcoma stem cell biomarkers CD117 and Stro-1 in the observation group and control group. The correlation between CD117 and Stro-1 protein expression in osteosarcoma tissues was observed. The relationship between the expression of CD117, Stro-1 as well as the double positive expression of CD117/Stro-1 protein and the clinicopathological factors and DFS of patients with osteosarcoma was assessed.Result:In observation group, the positive expression rates of CD117 and Stro-1 were 51.72% (30/58) and 48.28% (28/58) respectively. In control group, the positive expression rates were both 6/13, of which the differences showed no significance (all P values>0.05). In observation group, the positive expression of CD117 protein was positively correlated with that of Stro-1 protein (r n=0.864, P<0.01). The differences in the expression of CD117, Stro-1 and the dual positive expression of CD117/Stro-1 were significant in Enneking surgical staging (χ 2=6.501, 7.374, 6.130, all P values<0.05), but not in the age and gender of patients (all P values>0.05). Median DFS of 30 patients with positive expression of CD117 was 360.00 days, which was less than that of 30 patients with negative expression, 1 260.00 days. Median DFS of 28 patients with positive expression of Stro-1 was 330.00 days, which was less than that of 30 patients with negative expression, 900.00 days. Median DFS of 27 patients with dual positive CD117 and Stro-1 protein was 360.00 days, which was less than that of 31 patients without dual positive expression, 900.00 days. The differences were statistically significant (χ 2 = 5.770, 4.638, 5.391, all P values<0.05). Conclusions:The positive expressions of osteosarcoma stem cell biomarkers CD117 and Stro-1 in osteosarcoma tissues are positively correlated. No matter which protein is positive, patients have higher clinical stage and the shorter tumor-free survival time. CD117 and Stro-1are expected to be an important index to predict the postoperative prognosis of patients with osteosarcoma.

CD133 Expression in Osteosarcoma and Derivation of CD133+ Cells

Cd133 Expression Predicts Lung Metastasis And Poor Prognosis In Osteosarcoma Patients: A Clinical And Experimental Study

The prognostic role of CD133 expression in patients with osteosarcoma

CD133(+) CD44(+) Cells Mediate in the Lung Metastasis of Osteosarcoma.

Analysis of microRNA expression in CD133 positive cancer stem‐like cells of human osteosarcoma cell line MG-63

Isolation and Identification of Osteosarcoma Stem-Like Cells

CD271+ Osteosarcoma Cells Display Stem-Like Properties.

Identification of Tumorigenicity-Associated Genes in Osteosarcoma Cell Lines Based on Bioinformatic Analysis and Experimental Validation.

Quantitative Analyses of CD133 Expression Facilitate Researches on Tumor Stem Cells.

Phenotypic Characterization of Drug Resistance and Tumor Initiating Cancer Stem Cells from Human Bone Tumor Osteosarcoma Cell Line Os-77

Characteristics of CD133-Sustained Chemoresistant Cancer Stem-Like Cells in Human Ovarian Carcinoma

The CD24+ Cell Subset Promotes Invasion and Metastasis in Human Osteosarcoma

Description of the CD 133 + Subpopulation of the Human Ovarian Cancer Cell Line OVCAR 3

Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line

Cisplatin-resistant Osteosarcoma Cells Possess Cancer Stem Cell Properties in a Mouse Model

Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion Via Targeting IGF-1R

Osteosarcoma Stem Cells Have Active Wnt/β-catenin and Overexpress SOX2 and KLF4

CD49b Inhibits Osteogenic Differentiation and Plays an Important Role in Osteosarcoma Progression.

Expression of Aldehyde Dehydrogenase and Cd133 Defines Ovarian Cancer Stem Cells

Expression and clinical significance of CD117 and Stro-1 in osteosarcoma stem cell surface biomarkers